Session: 653. Multiple Myeloma: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Research, Translational Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Emerging technologies, Technology and Procedures, Profiling, Molecular testing, Omics technologies
Methods: In total, matched blood and BM samples were collected in 17 MM patients with active disease. For serial follow-up of the mutation profile, we performed targeted gene sequencing (using a 165-gene panel) on 35 matched BM and cfDNA samples collected in 15 MM patients at 2 or more different time points during a 5-year follow-up period. Classification of Single Nucleotide Variants (SNVs) was done based on the Belgian ComPerMed guidelines. For the methylation profiling, we investigated the genome-wide methylation status of CpG islands in paired BM and cfDNA samples of 5 MM patients with advanced disease using the NEBNext Enzymatic Methyl-seq kit (EM-seqTM) (New England Biolabs Inc., Massachusetts, USA). Pooled sequencing data from mononuclear cells-derived DNA from a group of healthy controls (n = 4) was used as reference material. Both genomic DNA (gDNA) and cfDNA from human myeloma cell lines (HMCLs) cultured in vitro (OPM-2, U266, XG-7 and RPMI-8226) was used as a positive control. The bioinformatics analysis of the raw sequencing data involved the identification of differentially methylated regions (DMRs), with further annotation to the reference genome using the methylKit R package.
Results: When focusing on the serial mutation analysis, our results indicate that cfDNA outperforms BM-DNA, as cfDNA and BM-DNA permitted the detection of 38/41 (93%) and 35/41 (85%) of unique SNVs found in this cohort, respectively. We detected 28 mutated genes, with the highest mutation frequencies observed in NRAS (27%), DNMT3A (20%), TP53 (20%) and DIS3 (20%). Notably, cfDNA permitted the detection of 4 (likely) pathogenic variants that were undetectable in BM-DNA. Additionally, our data in cfDNA confirm the previously made observation that the extent of changes at the genetic level is correlated with the depth of clinical response in MM. When performing the epigenetic profiling, we detected previously described hypermethylation in CDKN2A, RASSF4, CDH1 and RASSF1A in cfDNA and gDNA of HMCLs using EM-Seq. In total, 9794 DMRs were identified in the 5 MM patients we studied so far. Importantly, cfDNA permitted to detect 3349/4093 (82%) of DMRs found in matched BM-DNA.
Conclusion: Our results demonstrate the potential of cfDNA as a tool to monitor the dynamic mutation profile in MM and to correlate these results with the clinical response. The presence of SNVs only detected in cfDNA and not in matched BM-DNA highlights the added value of this strategy. In addition, our results indicate that cfDNA has the potential to be used as a biomarker for methylation profiling in MM. Future research should confirm these observations on larger patient cohorts. The introduction of serial cfDNA analysis into clinical settings could improve existing risk stratification and inform clinicians about the emergence of prognostically relevant and therapy resistance-associated (epi)genetic alterations, hence contributing to personalized medicine in MM.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts